TNF and temporal arteritis: Unfortunately placebo-controlled trials utilizing TNF-inhibition with infliximab [73], etanercept [74], and adalimumab [75] have failed to show significant therapeutic efficacy in patients with GCA and did not result in significant reduction of GC use or adverse events.